GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ￥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.

Tianjin Chase Sun Pharmaceutical Co., Ltd. is a listed pharmaceutical company with market value of over RMB 10 billion.  It's a high-tech pharmaceutical health industry cluster that covers TCM granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services and other areas.   Since 2015, the company has been ranked among the Top 100 Enterprises in China’s Pharmaceutical Industry.

For many years, Chase Sun has been focusing on researches and innovations in the five drug areas of critical, neoplastic, cardio-cerebrovascular, respiratory and neurodegenerative diseases, and dedicated to reducing China’s ICU fatality rate. It has already developed ace product catalog with independent IPRs represented by Xuebijing® injection and other first-aid medicines for critical diseases. A paper on RCT for Xuebijing’s Efficacy in Treatment of SCAP was published on the authoritative international critical medicine journal of Critical Care Medicine (CCM) in 2019 with corresponding authors of Prof. Bai Chunxue, Zhongshan Hospital, Fudan University and Shang Hongcai, Research Fellow of Dongzhimen Hospital, Beijing University of Chinese Medicine as well as first author of Prof. Song Yuanlin, Zhongshan Hospital, Fudan University. According to research, Xuebijing®reduced fatality rate of patients with severe pneumonia by 8.8%, made significant breakthrough in research methodology for evidence-based traditional Chinese medicine, reflected concrete clinical value of reduction of fatality rate of critical diseases, and created a new treatment pattern featured by combined use of Chinese and western medicine for patients with critical diseases.

L.E.K. Consulting is a global strategy consulting firm that specializes in corporate strategy, transaction services, and performance improvement. Founded in 1983, we now have more than 1,500 professionals located across major economies worldwide. Clients include Fortune 500, FTSE 100, Eurotop 300, and many of the largest firms in Asia-Pacific.

With a reputation for solving the most complex issues, L.E.K. collaborates closely with business leaders and their teams to accelerate the pace and precision of strategic decision-making. L.E.K. works across numerous industry sectors including a strong focus on the healthcare sector.

As a leading strategic advisor to the life sciences industry, L.E.K.’s clients include the largest and most advanced pharmaceutical, biotech, medical devices, tools and diagnostics companies. L.E.K.’s global team of life sciences professionals has expertise across all major industry segments and therapeutic areas, and we provide support at each stage of the product life cycle, from drug discovery to commercial optimisation.

L.E.K. hosts the Asia Pacific Life Sciences Centre of Excellence in partnership with the Singapore Economic Development Board (“EDB”). This Centre of Excellence (“CoE”) drives thought leadership and innovation to elevate the life sciences ecosystem both in Singapore and across the region.